Sherine Chan is the CEO and a Co-Founder of Neuroene Therapeutics. She is a mitochondrial biologist with a B.Sc. Hons. in Vet. Biology (Murdoch University) and a Ph.D. in Clinical Biochemistry (University of Western Australia). After a postdoctoral fellowship at NIEHS/NIH, she moved to the Medical University of South Carolina to start her lab in Drug Discovery, where she rose to Associate Professor. Her group developed new animal models and assays of mitochondrial dysfunction to understand the progression of mitochondrial disease and screen novel mitochondrial compounds. She and medicinal chemist Dr. James Chou discovered that small Vitamin K analogs had potent activity in animal models of seizure, Parkinson's, and mitochondrial diseases, leading them to co-found Neuroene. Dr. Chan now runs Neuroene full-time and recently moved the company to JLABS @ Washington, DC, as Neuroene was selected to join Blue Knight, a joint initiative between Johnson & Johnson Innovation and BARDA.